Can you take Iobenguane I 131 with Medex-LA?
1 drug interaction and 14 additional warnings found for the following 2 drugs:
- iobenguane I 131
- Medex-LA (guaifenesin/phenylpropanolamine)
Drug interactions
Major drug interactions
Major:
phenylpropanolamine iobenguane I-131
Applies to: Medex-LA (guaifenesin / phenylpropanolamine) and iobenguane I 131
Phenylpropanolamine may interfere with the effects of iobenguane I-131 in treating your condition. Let your doctor know you are receiving or have recently received phenylpropanolamine if you are being prescribed iobenguane I-131. You may need to stop using phenylpropanolamine for a certain amount of time before and after starting treatment with iobenguane I-131. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
phenylpropanolamine Food/Lifestyle
Applies to: Medex-LA (guaifenesin / phenylpropanolamine)
Using phenylpropanolamine with alcohol can increase the risk of cardiovascular side effects such as increased heart rate, chest pain, or blood pressure changes. In addition, you may also be more likely to experience nervous system side effects such as dizziness, drowsiness, depression, and difficulty concentrating. You should avoid or limit the use of alcohol while being treated with phenylpropanolamine. Do not use more than the recommended dose of phenylpropanolamine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.
Moderate:
phenylpropanolamine Caffeine
Applies to: Medex-LA (guaifenesin / phenylpropanolamine)
Both phenylpropanolamine and caffeine can increase blood pressure and heart rate, and combining them may enhance these effects. Talk to your doctor before using these medications, especially if you have a history of high blood pressure or heart disease. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
12 potential interactions Applies to: 12 conditions, including High Blood Pressure, Underactive Thyroid, Benign Prostatic Hyperplasia, Hyperthyroidism, and Psychosis.
Benign Prostatic Hyperplasia
Moderate:
Medex-LA
The phenylpropanolamine in Medex-LA has a moderate potential interaction with Benign Prostatic Hyperplasia.
Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.
Cardiovascular Conditions and Disorders
Major:
Medex-LA
The phenylpropanolamine in Medex-LA has a major potential interaction with Cardiovascular Conditions and Disorders.
Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.
Cerebrovascular Insufficiency
Major:
Medex-LA
The phenylpropanolamine in Medex-LA has a major potential interaction with Cerebrovascular Insufficiency.
Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.
Diabetes Mellitus
Moderate:
Medex-LA
The phenylpropanolamine in Medex-LA has a moderate potential interaction with Diabetes Mellitus.
Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.
Glaucoma/Intraocular Hypertension
Moderate:
Medex-LA
The phenylpropanolamine in Medex-LA has a moderate potential interaction with Glaucoma/Intraocular Hypertension.
Sympathomimetic agents can induce transient mydriasis via stimulation of alpha-1 adrenergic receptors. In patients with anatomically narrow angles or narrow-angle glaucoma, pupillary dilation can provoke an acute attack. In patients with other forms of glaucoma, mydriasis may occasionally increase intraocular pressure. Therapy with sympathomimetic agents should be administered cautiously in patients with or predisposed to glaucoma, particularly narrow-angle glaucoma.
High Blood Pressure
Moderate:
iobenguane I 131
The iobenguane I-131 in iobenguane I 131 has a moderate potential interaction with High Blood Pressure.
Eleven percent of patients who received a therapeutic dose of iobenguane I-131 experienced a worsening of preexisting hypertension defined as an increase in systolic blood pressure to =160 mmHg with an increase of 20 mmHg or an increase in diastolic blood pressure to = 100 mmHg with an increase of 10 mmHg. All changes in blood pressure occurred within the first 24 hours post infusion. Blood pressure should be frequently monitored during the first 24 hours after each therapeutic dose of iobenguane I-131.
Hyperthyroidism
Major:
Medex-LA
The phenylpropanolamine in Medex-LA has a major potential interaction with Hyperthyroidism.
Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.
Prostate Tumor, Benign
Moderate:
Medex-LA
The phenylpropanolamine in Medex-LA has a moderate potential interaction with Prostate Tumor, Benign.
Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.
Psychiatric Disorders
Moderate:
Medex-LA
The phenylpropanolamine in Medex-LA has a moderate potential interaction with Psychiatric Disorders.
Phenylpropanolamine may precipitate or exacerbate psychotic symptoms, particularly at high dosages. Therapy with phenylpropanolamine should be administered cautiously in patients with a history of psychiatric disorders.
Psychosis
Moderate:
Medex-LA
The phenylpropanolamine in Medex-LA has a moderate potential interaction with Psychosis.
Phenylpropanolamine may precipitate or exacerbate psychotic symptoms, particularly at high dosages. Therapy with phenylpropanolamine should be administered cautiously in patients with a history of psychiatric disorders.
Renal Dysfunction
Moderate:
iobenguane I 131
The iobenguane I-131 in iobenguane I 131 has a moderate potential interaction with Renal Dysfunction.
Renal failure or acute kidney injury and a demonstrated clinically significant decrease in glomerular filtration rate (GFR) has been reported in some patients receiving iobenguane I-131. Monitor renal function during and after treatment with iobenguane I-131. Patients with baseline renal impairment may be at greater risk of toxicity, and their radiation dose may be increased due to the delayed elimination of the drug. Adjust the therapeutic dose based on radiation exposure estimates from the dosimetry assessment. Perform more frequent assessments of renal function in patients with mild or moderate impairment. Iobenguane I-131 has not been studied in patients with severe renal impairment (creatinine clearance <30 mL/min), or end-stage renal disease.
Underactive Thyroid
Moderate:
iobenguane I 131
The iobenguane I-131 in iobenguane I 131 has a moderate potential interaction with Underactive Thyroid.
Hypothyroidism was reported in patients who received a therapeutic dose of iobenguane I-131. Caution and close monitoring is advised in patients with history of hypothyroidism. Initiate thyroid- blocking medications starting at least 1 day before and continuing for 10 days after each iobenguane I-131 dose to reduce the risk of hypothyroidism or thyroid neoplasia. Evaluate for clinical evidence of hypothyroidism and measure thyroid-stimulating hormone (TSH) levels prior to initiating treatment with iobenguane I-131 and annually thereafter.
Report options
More resources
iobenguane I 131
A total of 313 drugs are known to interact with iobenguane I 131.
- Iobenguane i 131 is in the drug class therapeutic radiopharmaceuticals.
- Iobenguane i 131 is used to treat the following conditions:
Medex-LA
A total of 207 drugs are known to interact with Medex-LA.
- Medex-la is in the drug class upper respiratory combinations.
- Medex-la is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.